Abstract:Objective: To explore the clinical and prognostic values of TP53 gene mutation in patients with acute myeloid leukemia (AML) . Methods: A retrospective analysis of 265 newly diagnosed AML patients with next-generation sequencing (NGS) data in the Hematology Department of Changhai Hospital from January 2010 to January 2019 was performed. Mutation analysis was carried out by targeted sequencing technology including 200 hematological malignancy related genes. The association of TP53 mutation with clinical features was analyzed. Results: Alterations in TP53 were found in 20 (7.5%) patients, including 17 case (6.4%) of missense mutations, 2 cases (0.7%) of frame-shift deletion mutations and 1 case (0.4%) of splicing sites mutation. A total of 23 kinds of TP53 mutations were detected, most of them (16, 69.6%) were located in the DNA binding domain of exon 5-8, 4 in the DNA binding domain of exon 3-4, 2 in exon 10 and 1 in splice site, respectively. The median age of patients with TP53 alterations was higher than those without [52 (26-72) years old vs 45 (14-75) years old, P= 0.008]. The frequency of complex karyotypes was higher in patients with TP53 alterations than those without [45.0% (9/20) vs 6.1% (15/245) , P<0.001]. Median overall survival (OS) of patients with TP53 alterations was shorter than those without[14.1 (95%CI 6.78-21.42) months vs 31.4 (95%CI 13.20-49.59) months, P=0.029]. The OS of patients treated with "Decitabine + CAG" was superior than that of patients treated with "3 + 7" regimen [30.0 (95%CI 27.35-38.84) months vs 12.5 (95%CI 5.80-19.19) months, P=0.018]. Multivariate analysis indicated that TP53, DNMT3A and USH2A alterations, WBC ≥ 12.45×10(9)/L had negative impacts on OS. Conclusion: The frequency of TP53 mutation was 7.5% in our cohort. Most mutations were located in the DNA binding domain. TP53 alterations were strongly associated with older age, complex karyotype and shorter OS. Decitabine-based induction chemotherapy and hematopoietic stem cell transplantation may improve OS, more cases and/or multicenter randomized studies are needed for further confirmation.

What have we learned about TP53- mutated acute myeloid leukemia?

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation

Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion

TP53 signal pathway confers potential therapy target in acute myeloid leukemia

Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia

TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches

The Role of TP53 in Acute Myeloid Leukemia: Challenges and Opportunities

Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of TP53 mutations in a real-world setting

Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms

Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment

Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia

TP53 in MDS and AML: Biological and Clinical Advances.

TP53 Copy Number and Protein Expression Inform Mutation Status across Risk Categories in Acute Myeloid Leukemia

The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia

[Clinical and Prognostic Values of TP53 Mutation in Patients with Acute Myeloid Leukemia].

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Haploidentical Haematopoietic Stem Cell Transplantation for TP53‐mutated Acute Myeloid Leukaemia

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML

Molecular and clinical significance of FLT3, NPM1, DNMT3A and TP53 mutations in acute myeloid leukemia patients

Challenges and emerging therapeutic strategies for TP53-mutated acute myeloid leukemia: still disappointing findings?

Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia